Figure 4 | Scientific Reports

Figure 4

From: The Toll–Like Receptor 2/6 Agonist, FSL–1 Lipopeptide, Therapeutically Mitigates Acute Radiation Syndrome

Figure 4

FSL–1 drives splenic EMH. Male C57BL/6 mice were administered physiological water (NT) or 0.25 mg/kg FSL–1 at 24 hours post 9.2 Gy TBI (n = 6–15 mice per group). (a) Spleens were harvested at 3, 9, 17 and 31 days after TBI, with weights shown. Each symbol represents one mouse. (b) Representative images of H&E stained spleen sections are shown. (c) Spleen EMH is quantified based on a scale described in Methods and represented as mean ± s.e.m. All data are representative of 3 independent experiments. ****P < 0.0001 between TBI, NT and TBI, FSL–1–treated mice. ++ P < 0.01 or +++ P < 0.001 between TBI, FSL–1 and FSL–1–treated mice. δ P < 0.05, δδδ P < 0.001 or δδδδ P < 0.0001 between TBI, NT and NT control mice.

Back to article page